While recapitulating many features of human NSCLC, KRAS mutant GEMMs differ in that they are unable to evoke strong anti-tumor immune responses, thus potentially lacking patient faithful responses to pharmacological intervention. This evidence concerns the gene KRAS and non-small cell lung carcinoma.